Moderna gets $590M from US government

Moderna Receives $590M From HHS To Develop Bird Flu Vaccine
TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
HHS gives Moderna $590M to 'accelerate' bird flu vaccine trials
The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains with pandemic potential.
Moderna Gets $590 Million to Develop Bird Flu Vaccine
The government is working to head off human bird flu infections. The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna Nabs Another $590M from HHS for mRNA-Based Bird Flu Vaccines
The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready before bird flu strains currently circulating in the wild and on farms can potentially cause human outbreaks.
Moderna Awarded $590 Million for Bird Flu Vaccine Development
The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of mRNA-based pandemic influenza vaccines, including vaccines for avian flu strains, to ensure the United States is better prepared for future potential pandemics, according to a recent HHS news release.
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023.
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under Trump
Shares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a $590 million award from the U.S. Health and Human Services Department to accelerate its bird flu vaccine development.

MicroStrategy, Trump Media, Moderna, Walgreens

Where Will Moderna Be in 3 Years?
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
3-Stock Lunch: 3M, Moderna, & T-Mobile
Eva Ados, ERshares COO and chief investment strategist, joins CNBC's 'Power Lunch' to share outlooks on three stocks.
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Is Moderna Stock a Buy?
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Why Is Moderna Stock Trading Higher On Tuesday?
Earlier this month, Moderna announced business updates and progress across its pipeline. Moderna says it enters 2025 with a ...
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Why Moderna (MRNA) Stock Is Advancing Today
RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by ...